

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hu *et al.*

Appl. No. 09/033,662

Filed: March 3, 1998

For: **Human Vascular Endothelial  
Growth Factor 3**



Art Unit: 1646

Examiner: Saoud, C.

Atty. Docket: 1488.1040001

**Reply Under 37 C.F.R. § 1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Office Action dated March 2, 2000, (PTO Prosecution File Wrapper Paper No. 14), Applicants submit the following Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

**Remarks**

Based on the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

**Rejections under 35 U.S.C. § 102**

The Examiner rejected claims 30-32, 34-37, 42-44, 46-49, 52-56 and 61-65 under 35 U.S.C. § 102(e) as allegedly being anticipated by Eriksson *et al.*, U.S. Patent No. 5,928,939. Applicants respectfully traverse this rejection.

The captioned application claims priority benefit of U.S. Appl. No. 08/469,641, filed June 6, 1995. All of the pending claims find support in the priority application. In particular, support

RECEIVED  
JUN - 5 2000  
TC 1600 MAIL ROOM